All companies, by operating margin
508 companies and 2239 sets of results: the S&P 500, and sometimes a company from outside it. We can draw the statement for 418.
| # | Company | Market cap | Share price | Operating margin | Quarter |
|---|---|---|---|---|---|
| 51 |
|
$94.4B | $60.58 −0.1% | 34% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 USB U.S. Bancorp |
| 52 |
|
$33.0B | $79.95 +2.1% | 34% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 ZTS Zoetis |
| 53 |
|
$5.07T | $347.33 −0.5% | 33% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 AAPL Apple |
| 54 |
|
$114B | $151.45 +0.7% | 33% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 BKNG Booking |
| 55 |
|
$86.0B | $164.04 +1.1% | 33% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 EOG EOG Resources |
| 56 |
|
$99.4B | $135.48 −2.6% | 33% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 FTNT Fortinet |
| 57 |
|
$3.42T | $279.47 −1.5% | 33% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 GOOGL Alphabet |
| 58 |
|
$35.5B | $245.85 −2.8% | 33% Last four quarters 2027: Q1 · 2026: Q2, Q3, Q4 | Q1 FY27 RMD ResMed |
| 59 |
|
$17.1B | $265.59 +0.1% | 32% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 ESS Essex Property Trust |
| 60 |
|
$45.6B | $579.29 +0.6% | 32% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 IDXX Idexx Laboratories |
| 61 |
|
$400B | $132.18 −5.3% | 32% Last four quarters 2027: Q1 · 2026: Q2, Q3, Q4 | Q1 FY27 ORCL Oracle |
| 62 |
|
$22.6B | $132.45 +2.4% | 32% Last four quarters 2027: Q1 · 2026: Q2, Q3, Q4 | Q1 FY27 STZ Constellation Brands |
| 63 |
|
$261B | $62.58 +0.9% | 31% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 NFLX Netflix |
| 64 |
|
$11.4B | $35.49 +0.2% | 31% Last four quarters 2026: Q1 · 2025: Q2, Q3, Q4 | Q1 FY26 UDR UDR |
| 65 |
|
$42.8B | $156.93 +1.6% | 31% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 YUM Yum! Brands |
| 66 |
|
$317B | $400.00 −5.1% | 30% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 AMAT Applied Materials |
| 67 |
|
$254B | $470.15 +2.0% | 30% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 AMGN Amgen |
| 68 |
|
$59.5B | $106.50 +0.8% | 30% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 NDAQ Nasdaq |
| 69 |
|
$46.7B | $170.07 −2.1% | 30% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 STT State Street |
| 70 |
|
$43.4B | $277.87 −6.2% | 30% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 TER Teradyne |
| 71 |
|
$50.8B | $312.81 +0.8% | 30% Last four quarters 2027: Q1, Q2 · 2026: Q3, Q4 | Q2 FY27 VEEV Veeva Systems |
| 72 |
|
$75.6B | $33.96 +0.0% | 29% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 KMI Kinder Morgan |
| 73 |
|
$46.4B | $47.33 +2.1% | 29% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 MNST Monster Beverage |
| 74 |
|
$59.8B | $1,217.32 +1.5% | 29% Last four quarters 2026: Q1, Q2 · 2025: Q3, Q4 | Q2 FY26 MPWR Monolithic Power Systems |
| 75 |
|
$91.6B | $889.89 +8.7% | 29% Last four quarters 2026: Q1, Q2, Q3 · 2025: Q4 | Q3 FY26 REGN Regeneron Pharmaceuticals |
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.